Transcripta Bio raises $24 million in a Series A funding round led by Mayo Clinic and Omnimed to advance AI-powered drug discovery for neurological diseases.
Amount Raised
$24 Million
Round Type
Series A
Palo AltoBiotechnologyHealth CareArtificial IntelligenceTherapeuticsInvestors
Description
Transcripta Bio has announced it raised $24 million since its Series A. The funding will be used to advance IND-enabling studies and support clinical preparation for programs targeting Autism Spectrum Disorder and Facioscapulohumeral Muscular Dystrophy. The round included new participation from Mayo Clinic and Omnimed alongside existing investors. This capital aims to enhance their AI-powered drug discovery platform.
Who to call at Transcripta Bio, and when
A new round usually means Transcripta Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Transcripta Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Transcripta Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Transcripta Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Transcripta Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansTranscripta Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.